Advertisement

Annals of Surgical Oncology

, Volume 26, Issue 10, pp 3166–3177 | Cite as

Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma

  • M. J. Thornton
  • H. V. Williamson
  • K. E. Westbrook
  • R. A. Greenup
  • J. K. Plichta
  • L. H. Rosenberger
  • A. M. Gupta
  • T. Hyslop
  • E. S. Hwang
  • O. M. FayanjuEmail author
Breast Oncology
  • 155 Downloads

Abstract

Background

Neoadjuvant chemotherapy (NACT) is often recommended for patients with node-positive invasive lobular carcinoma (ILC) despite unclear benefit in this largely hormone receptor-positive (HR+) group. We sought to compare overall survival (OS) between patients with node-positive ILC who received neoadjuvant endocrine therapy (NET) and those who received NACT.

Methods

Women with cT1–4c, cN1–3 HR+ ILC in the National Cancer Data Base (2004–2014) who underwent surgery following neoadjuvant therapy were identified. Kaplan–Meier curves and Cox proportional hazards modeling were used to estimate unadjusted and adjusted overall survival (OS), respectively.

Results

Of the 5942 patients in the cohort, 855 received NET and 5087 received NACT. NET recipients were older (70 vs. 54 years) and had more comorbidities (Charlson–Deyo score ≥ 1: 21.1% vs. 11.5%), lower cT classification (cT3–4: 44.2% vs. 51.0%), lower rates of mastectomy (72.5% vs. 82.2%), lower rates of pathologic complete response (0% vs. 2.5%), and lower rates of postlumpectomy (73.2% vs. 91.0%) and postmastectomy (60.0% vs. 80.8%) radiation versus NACT recipients (all p < 0.001). NACT recipients had higher unadjusted 10-year OS versus NET recipients (57.9% vs. 36.0%), but after adjustment, there was no significant difference in OS between the two groups (p = 0.10).

Conclusions

Patients with node-positive ILC who received NET presented with smaller tumors, older age, and greater burden of comorbidities versus NACT recipients but had similar adjusted OS. While there is evidence from clinical trials supporting efficacy of NET in HR+ breast cancer, our findings suggest the need for further, histology-specific investigation regarding the optimal inclusion and sequence of endocrine therapy and chemotherapy in ILC.

Notes

Acknowledgment

Portions of this manuscript were presented as part of a podium presentation at the 2019 Annual Meeting of the American Society of Breast Surgeons (ASBrS) on May 4, 2019. The National Cancer Data Base (NCDB) is a joint project of the American Cancer Society and the Commission on Cancer (CoC) of the American College of Surgeons. Established in 1989, the NCDB is a nationwide, facility-based, comprehensive clinical surveillance resource oncology dataset that currently captures ~ 70% of all newly diagnosed malignancies in the USA annually. The data used in this study are derived from a deidentified NCDB Participant User File and have not been verified by the CoC or the American Cancer Society. The American College of Surgeons has established a data use agreement with each of its CoC-accredited hospitals; these overhead groups are not responsible for the analytic or statistical methodology employed or the conclusions drawn by the authors.

Funding

Dr. R. Greenup is supported by the National Institutes of Health (NIH) Office of Women’s Research Building Interdisciplinary Research Careers in Women’s Health Award Number K12HD043446 (PI: Andrews). Dr. O. Fayanju is supported by the National Center for Advancing Translational Sciences of the NIH under award no. 1KL2TR002554 (PI: Svetkey). This work is also supported by the Duke Cancer Institute through NIH grant P30CA014236 (PI: Kastan). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Disclosures

Thornton, Williamson, Westbrook, Greenup, Plichta, Rosenberger, Gupta, Hyslop, Hwang and Fayanju has nothing to disclose.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors. The study used deidentified information and was given exempt status by our Institutional Review Board (IRB).

Supplementary material

10434_2019_7564_MOESM1_ESM.docx (123 kb)
Supplementary material 1 (DOCX 122 kb)

References

  1. 1.
    Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778–85.CrossRefPubMedGoogle Scholar
  2. 2.
    Dixon JM, Renshaw L, Dixon J, Thomas J. Invasive lobular carcinoma: response to neoadjuvant letrozole therapy. Breast Cancer Res Treat. 2011;130(3):871–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Reed AEM, Kutasovic JR, Lakhani SR, Simpson PT. Invasive lobular carcinoma of the breast: morphology, biomarkers and ‘omics. Breast Cancer Res. 2015;17:12.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Petruolo OA, Pilewskie M, Patil S, et al. Standard pathologic features can be used to identify a subset of estrogen receptor-positive, HER2 negative patients likely to benefit from neoadjuvant chemotherapy. Ann Surg Oncol. 2017;24(9):2556–62.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23(1):41–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Petrelli F, Barni S. Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer. Breast Cancer Res Treat. 2013;142(2):227–35.CrossRefPubMedGoogle Scholar
  7. 7.
    Fayanju OM, Ren Y, Thomas SM, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg. 2018;268(4):591–601.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Boughey JC, Wagner J, Garrett BJ, et al. Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol. 2009;16(6):1606–11.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lips EH, Mukhtar RA, Yau C, et al. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat. 2012;136(1):35–43.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Sikora MJ, Jankowitz RC, Dabbs DJ, Oesterreich S. Invasive lobular carcinoma of the breast: patient response to systemic endocrine therapy and hormone response in model systems. Steroids. 2013;78(6):568–75.CrossRefPubMedGoogle Scholar
  11. 11.
    Barbie TU, Ma C, Margenthaler JA. Management of premenopausal women with neoadjuvant endocrine therapy: a single-institution experience. Ann Surg Oncol. 2015;22(12):3861–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–9.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Chiba A, Hoskin TL, Heins CN, Hunt KK, Habermann EB, Boughey JC. Trends in neoadjuvant endocrine therapy use and impact on rates of breast conservation in hormone receptor-positive breast cancer: a National Cancer Data Base study. Ann Surg Oncol. 2017;24(2):418–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Barroso-Sousa R, Silva DD, Alessi JV, Mano MS. Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives. Ecancermedicalscience. 2016;10:609.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1477–86.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Natarajan L, Pu M, Parker BA, et al. Time-varying effects of prognostic factors associated with disease-free survival in breast cancer. Am J Epidemiol. 2009;169(12):1463–70.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Vriens IJH, Keymeulen K, Lobbes MBI, et al. Breast magnetic resonance imaging use in patients undergoing neoadjuvant chemotherapy is associated with less mastectomies in large ductal cancers but not in lobular cancers. Eur J Cancer (Oxford, England: 1990). 2017;81:74–80.Google Scholar
  18. 18.
    Rakha EA, El-Sayed ME, Powe DG, et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer. 2008;44(1):73–83.CrossRefPubMedGoogle Scholar
  19. 19.
    Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6(3):R149–56.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Tubiana-Hulin M, Stevens D, Lasry S, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol. 2006;17(8):1228–33.CrossRefPubMedGoogle Scholar
  21. 21.
    Silverstein MJ, Lewinsky BS, Waisman JR, et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer. 1994;73(6):1673–7.Google Scholar
  22. 22.
    Coradini D, Pellizzaro C, Veneroni S, Ventura L, Daidone MG. Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer. 2002;87(10):1105–11.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Tamirisa NP, Vernia H, Thomas SM, et al. The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma. J Surg Oncol. 2019 May 6. [Epub ahead of print].Google Scholar
  24. 24.
    Truin W, Vugts G, Roumen RM, et al. Differences in response and surgical management with neoadjuvant chemotherapy in invasive lobular versus ductal breast cancer. Ann Surg Oncol. 2016;23(1):51–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Charehbili A, Fontein DBY, Kroep JR, et al. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review. Cancer Treat Rev. 2014;40(1):86–92.CrossRefPubMedGoogle Scholar
  26. 26.
    Bellavance EC, Kesmodel SB. Decision-making in the surgical treatment of breast cancer: factors influencing women’s choices for mastectomy and breast conserving surgery. Front Oncol. 2016;6:74.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Storm-Dickerson T, Das L, Gabriel A, Gitlin M, Farias J, Macarios D. What drives patient choice: preferences for approaches to surgical treatments for breast cancer beyond traditional clinical benchmarks. Plast Reconstr Surg Glob Open. 2018;6(4):e1746.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25(33):5203–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Suman VJ, Ellis MJ, Ma CX. The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer. Chin Clin Oncol. 2015;4(3):34.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Conlon N, Ross DS, Howard J, Catalano JP, Dickler MN, Tan LK. Is there a role for Oncotype Dx testing in invasive lobular carcinoma? Breast J. 2015;21(5):514–9.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Felts JL, Zhu J, Han B, Smith SJ, Truica CI. An analysis of Oncotype DX recurrence scores and clinicopathologic characteristics in invasive lobular breast cancer. Breast J. 2017;23(6):677–86.CrossRefPubMedGoogle Scholar
  32. 32.
    Beumer IJ, Persoon M, Witteveen A, et al. Prognostic value of MammaPrint((R)) in invasive lobular breast cancer. Biomark Insights. 2016;11:139–46.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717–29.Google Scholar
  34. 34.
    Kelly CM, Krishnamurthy S, Bianchini G, et al. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer. 2010;116(22):5161–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Anwar IF, Down SK, Rizvi S, et al. Invasive lobular carcinoma of the breast: should this be regarded as a chronic disease? Int J Surg. 2010;8(5):346–52.CrossRefPubMedGoogle Scholar
  36. 36.
    Pestalozzi BC, Zahrieh D, Mallon E, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008;26(18):3006–14.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • M. J. Thornton
    • 1
  • H. V. Williamson
    • 2
  • K. E. Westbrook
    • 2
    • 3
  • R. A. Greenup
    • 1
    • 2
  • J. K. Plichta
    • 1
    • 2
  • L. H. Rosenberger
    • 1
    • 2
  • A. M. Gupta
    • 1
  • T. Hyslop
    • 2
    • 4
  • E. S. Hwang
    • 1
    • 2
  • O. M. Fayanju
    • 1
    • 2
    • 5
    Email author
  1. 1.Department of SurgeryDuke University Medical CenterDurhamUSA
  2. 2.Duke Cancer InstituteDuke University Medical CenterDurhamUSA
  3. 3.Department of MedicineDuke University Medical CenterDurhamUSA
  4. 4.Department of Biostatistics and BioinformaticsDuke UniversityDurhamUSA
  5. 5.Durham VA Medical CenterDurhamUSA

Personalised recommendations